ISRCTN61384873 https://doi.org/10.1186/ISRCTN61384873

A double-blind placebo controlled randomised trial of oral sodium clodronate for locally advanced prostatic adenocarcinoma

Submission date 06/04/2000	**Recruitment status** No longer recruiting	[_] Prospectively registered [_] Protocol [_] Statistical analysis plan [X] Results [_] Individual participant data
Registration date 06/04/2000	**Overall study status** Completed	
Last Edited 12/04/2012	**Condition category** Cancer	

Plain English summary of protocol
http://www.ctu.mrc.ac.uk/research_areas/study_details.aspx?s=59

Contact information

Type(s)
Scientific

Contact name
Mr Matthew Sydes

Contact details
MRC Clinical Trials Unit
222 Euston Road
London
United Kingdom
NW1 2DA
+44 (0)207 6704700
matthew.sydes@ctu.mrc.ac.uk

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers
PR04

Study information

Scientific Title

Study objectives
To measure the efficacy and safety of clodronate in preventing symptomatic bone metastases

Ethics approval required
Old ethics approval format

Ethics approval(s)
Not provided at time of registration

Study design
Double-blind placebo controlled randomised trial

Primary study design
Interventional

Secondary study design
Randomised controlled trial

Study setting(s)
Not specified

Study type(s)
Treatment

Participant information sheet

Health condition(s) or problem(s) studied
Prostate cancer

Interventions
1. One group receives five years of oral sodium clodronate
2. The other group receives matching placebo for five years

Intervention Type
Drug

Phase
Not Specified

Drug/device/biological/vaccine name(s)
Oral sodium clodronate

Primary outcome measure

1. Time to symptomatic bone metastases
2. Overall survival

Secondary outcome measures
Not provided at time of registration

Overall study start date
01/06/1994

Completion date
01/11/1997

Eligibility

Key inclusion criteria
1. Histological diagnosis of adenocarcinoma of the prostate
2. TNM categories T2-T4, N0-N3, NX, M0
3. No evidence of bone metastases on bone scan within 4 weeks of randomisation
4. No known nodal disease outside pelvis
5. Normocalcaemic (serum calcium within the normal range of the participating centre)
6. Patients may be treated with any standard management policy for localised disease (radiotherapy, surgery, androgen deprivation or observation) or have had such treatment in the past
7. WHO performance status of 0, 1 or 2
8. No concomitant or previous use of other bisphosphonates
9. Serum creatinine less than two times upper limit of normal range of the centre
10. No administration of any investigational drug within 12 months
11. Diagnosis of disease within last 3 years

Participant type(s)
Patient

Age group
Adult

Sex
Male

Target number of participants
500

Key exclusion criteria
Does not match inclusion criteria

Date of first enrolment
01/06/1994

Date of final enrolment
01/11/1997

Locations

Countries of recruitment
England

United Kingdom

Study participating centre
MRC Clinical Trials Unit
London
United Kingdom
NW1 2DA

Sponsor information

Organisation
Medical Research Council (MRC) (UK)

Sponsor details
20 Park Crescent
London
United Kingdom
W1B 1AL
+44 (0)20 7636 5422
clinical.trial@headoffice.mrc.ac.uk

Sponsor type
Research council

Website
http://www.mrc.ac.uk

Funder(s)

Funder type
Research council

Funder Name
Medical Research Council (MRC) (UK)

Alternative Name(s)
Medical Research Council (United Kingdom), UK Medical Research Council, MRC

Funding Body Type
Government organisation

Funding Body Subtype
National government

Location
United Kingdom

Results and Publications

Publication and dissemination plan
Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary
Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	16/05/2007		Yes	No
Results article	results	01/09/2009		Yes	No